Financial incentives double quit rates among smokers

Offering small financial incentives doubles smoking cessation rates among socioeconomically disadvantaged smokers, according to research published in the American Journal of Public Health (2014; doi:10.2105/AJPH.2014.302102).

Tobacco use is the leading cause of preventable death in the United States, according to the Centers for Disease Control and Prevention. Thanks to public health efforts, smoking rates have declined to 18% among American adults. However, nearly 30% of people living in poverty continue to smoke. Smoking is becoming increasingly concentrated in socioeconomically disadvantaged populations, according to the study authors.

“We wanted to investigate how small and potentially cost-effective financial incentives might help safety net hospital patients quit smoking,” said Darla Kendzor, PhD, assistant professor in the Division of Health Promotion and Behavioral Sciences at The University of Texas Health Science Center at Houston (UTHealth), School of Public Health, Dallas Regional Campus. Safety net hospitals provide a significant level of care to low-income, uninsured, and vulnerable populations.

Researchers enrolled Parkland Smoking Cessation Clinic patients in Dallas from 2011 to 2013. Participants were randomly assigned to either usual clinic care or the intervention group. Usual care included an educational orientation session, weekly support group meetings, physician visits, and pharmacologic treatment. The intervention group received usual care and small financial incentives for biochemically verified smoking abstinence.

Specifically, participants in the intervention group had the opportunity to earn $20 in gift cards for abstinence on the quit date, and this amount increased by $5 each week for continued abstinence up to $40. Thus, participants could earn up to $150 in gift cards over 4 weeks. Progress was monitored for 12 weeks following the quit date.

Abstinence rates were significantly higher for those assigned to the intervention group at all visits following the quit date, with 49% remaining abstinent versus 25% of usual-care participants at 4 weeks after the quit date. Twelve weeks after the quit date and 8 weeks after incentives were discontinued, 33% of the financial-incentives group were abstinent versus 14% in the usual-care group.

Participants earned an average of $63 in gift cards for abstinence during the first 4 weeks after the quit date. The clinic sees about 200 patients a year, so the cost to the clinic is estimated to be about $12,680. In contrast, the average cost of lung cancer treatment ranged from $60,533 to $73,062 per person in 2010, according to research from the National Cancer Institute.

The low cost of this cessation program could outweigh health care costs associated with smoking-related illnesses, such as cardiovascular diseases, respiratory diseases, and cancer, according to Kendzor.

Participants recruited from the Parkland Smoking Cessation Clinic were extremely socioeconomically disadvantaged. Most had an average household income of less than $12,000 a year. Also, 85% were not employed and more than half were uninsured.

“We found that women assigned to the financial incentives intervention had the highest cessation rates, which was surprising because women often have lower cessation rates than men participating in treatment,” said Kendzor.

Kendzor hopes to evaluate the longer-term effects of financial incentives on cessation by following participants for 6 months or longer. Funding for this study came from the UTHealth School of Public Health and the American Cancer Society.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs